194 related articles for article (PubMed ID: 12074786)
1. DNA alterations in body fluids as molecular tumor markers for urological malignancies.
Goessl C; Müller M; Straub B; Miller K
Eur Urol; 2002 Jun; 41(6):668-76. PubMed ID: 12074786
[TBL] [Abstract][Full Text] [Related]
2. [Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples].
Müller M; Goessl C; Krause H; Miller K
Urologe A; 2003 May; 42(5):660-8. PubMed ID: 12750801
[TBL] [Abstract][Full Text] [Related]
3. DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies.
Larsen LK; Lind GE; Guldberg P; Dahl C
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151158
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic biomarkers in the blood of patients with urological malignancies.
Ellinger J; Müller SC; Dietrich D
Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C; Krause H; Müller M; Heicappell R; Schrader M; Sachsinger J; Miller K
Cancer Res; 2000 Nov; 60(21):5941-5. PubMed ID: 11085508
[TBL] [Abstract][Full Text] [Related]
6. The study of DNA methylation in urological cancer: present and future.
Andrés G; Ashour N; Sánchez-Chapado M; Ropero S; Angulo JC
Actas Urol Esp; 2013 Jun; 37(6):368-75. PubMed ID: 23643196
[TBL] [Abstract][Full Text] [Related]
7. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.
Carvalho AL; Jeronimo C; Kim MM; Henrique R; Zhang Z; Hoque MO; Chang S; Brait M; Nayak CS; Jiang WW; Claybourne Q; Tokumaru Y; Lee J; Goldenberg D; Garrett-Mayer E; Goodman S; Moon CS; Koch W; Westra WH; Sidransky D; Califano JA
Clin Cancer Res; 2008 Jan; 14(1):97-107. PubMed ID: 18172258
[TBL] [Abstract][Full Text] [Related]
9. Methylation-based biomarkers for early detection of urological cancer.
Henrique R; Costa VL; Jerónimo C
Crit Rev Oncog; 2007 Dec; 13(4):265-82. PubMed ID: 18540830
[TBL] [Abstract][Full Text] [Related]
10. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
11. The potential use of urine cell free DNA as a marker for cancer.
Salvi S; Martignano F; Molinari C; Gurioli G; Calistri D; De Giorgi U; Conteduca V; Casadio V
Expert Rev Mol Diagn; 2016 Dec; 16(12):1283-1290. PubMed ID: 27796148
[TBL] [Abstract][Full Text] [Related]
12. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.
Ralla B; Stephan C; Meller S; Dietrich D; Kristiansen G; Jung K
Crit Rev Clin Lab Sci; 2014 Aug; 51(4):200-31. PubMed ID: 24878357
[TBL] [Abstract][Full Text] [Related]
13. DNA-based detection of prostate cancer in blood, urine, and ejaculates.
Goessl C; Müller M; Heicappell R; Krause H; Miller K
Ann N Y Acad Sci; 2001 Sep; 945():51-8. PubMed ID: 11708494
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
15. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2009 Oct; 104(7):896-901. PubMed ID: 19522860
[TBL] [Abstract][Full Text] [Related]
16. [Circulating cell-free serum DNA: significance as a new biomarker for urological malignancies].
Ellinger J; von Rücker A; Bastian PJ; Müller SC
Urologe A; 2010 Sep; 49(9):1131-2, 1134. PubMed ID: 20628864
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer.
Utting M; Werner W; Dahse R; Schubert J; Junker K
Clin Cancer Res; 2002 Jan; 8(1):35-40. PubMed ID: 11801538
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient.
Chang HW; Chan A; Kwong DL; Wei WI; Sham JS; Yuen AP
Int J Cancer; 2003 Jul; 105(6):851-5. PubMed ID: 12767073
[TBL] [Abstract][Full Text] [Related]
19. New Progress of Epigenetic Biomarkers in Urological Cancer.
Wu P; Cao Z; Wu S
Dis Markers; 2016; 2016():9864047. PubMed ID: 27594736
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation in urological malignancies (review).
Schulz WA
Int J Oncol; 1998 Jul; 13(1):151-67. PubMed ID: 9625817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
